Considerations into pharmacogenomics of COVID-19 pharmacotherapy: hope, hype and reality

dc.authoridAyşe Şeyma Büyük / 0000-0001-8934-0359en_US
dc.authoridSemra Şardaş / 0000-0001-5456-8636en_US
dc.authorscopusidAyşe Şeyma Büyük / 57215857903en_US
dc.authorscopusidSemra Şardaş / 7003286974en_US
dc.authorwosidAyşe Şeyma Büyük / AAM-1484-2020en_US
dc.authorwosidSemra Şardaş / DPM-9537-2022en_US
dc.contributor.authorAl Taie, Anmar
dc.contributor.authorBüyük, Ayşe Şeyma
dc.contributor.authorŞardaş, Semra
dc.date.accessioned2022-11-14T11:22:21Z
dc.date.available2022-11-14T11:22:21Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümüen_US
dc.description.abstractCOVID-19 medicines, such as molnupiravir are beginning to emerge for public health and clinical practice. On the other hand, drugs display marked variability in their efficacy and safety. Hence, COVID-19 medicines, as with all drugs, will be subject to the age-old maxim “one size prescription does not fit all”. In this context, pharmacogenomics is the study of genome-by-drug interactions and offers insights on mechanisms of patient-to-patient and between-population variations in drug efficacy and safety. Pharmacogenomics information is crucial to tailoring the patients' prescriptions to achieve COVID-19 preventive and therapeutic interventions that take into account the host biology, patients’ genome, and variable environmental exposures that collectively influence drug efficacy and safety. This expert review critically evaluates and summarizes the pharmacogenomics and personalized medicine aspects of the emerging COVID-19 drugs, and other selected drug interventions deployed to date. Here, we aim to sort out the hope, hype, and reality and suggest that there are veritable prospects to advance COVID-19 medicines for public health benefits, provided that pharmacogenomics is considered and implemented adequately. Pharmacogenomics is an integral part of rational and evidence-based medical practice. Scientists, health care professionals, pharmacists, pharmacovigilance practitioners, and importantly, patients stand to benefit by expanding the current pandemic response toolbox by the science of pharmacogenomics, and its applications in COVID-19 medicines and clinical trials.en_US
dc.identifier.citationAL-Taie, A., Büyük, A. Ş., & Sardas, S. (2022). Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Pulmonary Pharmacology and Therapeutics, 77 doi:10.1016/j.pupt.2022.102172en_US
dc.identifier.doi10.1016/j.pupt.2022.102172en_US
dc.identifier.scopus2-s2.0-85140765335en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1016/j.pupt.2022.102172
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3376
dc.identifier.volume77en_US
dc.identifier.wosWOS:000877679200002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBüyük, Ayşe Şeyma
dc.institutionauthorŞardaş, Semra
dc.language.isoenen_US
dc.publisherAcademic Pressen_US
dc.relation.ispartofPulmonary Pharmacology and Therapeuticsen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectClinical Trialsen_US
dc.subjectCOVID-19en_US
dc.subjectMolnupiraviren_US
dc.subjectPersonalized Medicineen_US
dc.subjectPharmacogenomicsen_US
dc.titleConsiderations into pharmacogenomics of COVID-19 pharmacotherapy: hope, hype and realityen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
1-s2.0-S1094553922000633-main.pdf
Boyut:
896.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: